Financial strategies for uncertain times
Inspite of current geopolitical disruptions,both larger pharma enterprises and smaller promoter-driven entities are playing for…
Author
India is well on its path to strongly push back the perception battle of quality
As we mark International Clinical Trial Day today, Dr Seema Pai, President, ISCR explains to Viveka Roychowdhury why it is…
JNPC: Carrying forward a 20-year old legacy
Billed as India’s first bulk drug, chemicals and allied manufacturing parks and one of the most successful public-private…
Sun Pharma bets on Organon for its next wind
Sun Pharma’s $12 billion acquisition of Organon will prove to be a milestone as the largest takeover by an Indian pharma company.…
Safeguarding the pharma excipients supply chain
Adding excipient details to QR codes of the top 300 drugs may not be a tough task. But as CDSCO plans to expand QR codes to cover…
Mumbai Experience Center reflects Agilent’s continued commitment to India
Bharat Bhardwaj, Vice President, Asia Pacific, Agilent Technologies spoke to Viveka Roychowdhury on why Agilent has been…
Midst global headwinds, CDSCO cracks down on GLP-1 gold rush
As pharma companies deal with price wars, increasing regulatory heat and a volatile geopolitical situation, navigating this…
Companies need to look at anti-counterfeiting solutions from the perspective of protecting revenue,…
Can you briefly explain ASPA’s evolution and how the anti‑counterfeiting ecosystem has changed?
ASPA as an organisation started…
Our approach is to combine localised production with global quality standards
What do you see as India’s role in the evolving global life sciences and biopharma value chain over the next decade?
India is…
Building India Pharma Inc’s innovation muscle
While we agree that “what got us here (an affordable generics powerhouse) will not get us there (a leader in pharma innovation)”,…